INAB (IN8bio) NonCurrent Deferred Liabilities: $0.00 Mil (As of Mar. 2026)


INAB IN8bio Inc INAB
28 GF Score
Price $1.32
View Full Analysis

What is IN8bio NonCurrent Deferred Liabilities?

IN8bio INAB -4.66% 28 NonCurrent Deferred Liabilities is $0.00 Mil as of Mar. 2026. GuruFocus rates INAB with a GF Score™ of 28/100.

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

IN8bio's non-current deferred liabilities for the quarter that ended in Mar. 2026 was $0.00 Mil.

IN8bio NonCurrent Deferred Liabilities Related Terms

IN8bio NonCurrent Deferred Liabilities Historical Data

* Premium members only.

The historical data trend for IN8bio's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

IN8bio NonCurrent Deferred Liabilities Chart

IN8bio Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
NonCurrent Deferred Liabilities
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

IN8bio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
INAB
28GF Score
IN8bio Inc INAB
NonCurrent Deferred Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a NonCurrent Deferred Liabilities of $0.00 Mil mean?
IN8bio (INAB) has a NonCurrent Deferred Liabilities of $0.00 Mil as of Mar. 2026. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on IN8bio and its competitors.
Is IN8bio's NonCurrent Deferred Liabilities too high?
IN8bio's current NonCurrent Deferred Liabilities is $0.00 Mil. Overall, IN8bio has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does IN8bio's NonCurrent Deferred Liabilities compare to GDTC and LEXX?
IN8bio's NonCurrent Deferred Liabilities of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Liabilities for a Biotechnology company?
A good NonCurrent Deferred Liabilities depends on the Biotechnology industry context. However, NonCurrent Deferred Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Liabilities mean?
A high NonCurrent Deferred Liabilities can signal that a stock is expensive relative to its fundamentals. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on IN8bio and its competitors. IN8bio's current NonCurrent Deferred Liabilities is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IN8bio stock overvalued right now?
IN8bio (INAB) has a current NonCurrent Deferred Liabilities of $0.00 Mil. The current NonCurrent Deferred Liabilities is $0.00 Mil. IN8bio's overall GF Score™ is 28/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Liabilities calculated?
NonCurrent Deferred Liabilities is calculated from a company's financial statements. For IN8bio (INAB), the current NonCurrent Deferred Liabilities is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

IN8bio Business Description

Address 350 5th Avenue, Suite 5330, New York, NY, USA, 10118
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.
28GF Score

Get the complete analysis for INAB

NonCurrent Deferred Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.32
Price